Stockreport

InspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard™ EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Hor...

InspireMD Inc.  (NSPR) 
NASDAQ:AMEX Investor Relations: inspiremd.com/en/investors/investor-relations
PDF TEL AVIV, Israel, Nov. 29, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention [Read more]